Approved anti-depressants typically report average MADRS improvements of ~2 to 3 points over placebo groups
The global antidepressants drugs market was valued at USD 17.02 billion in 2022 and growing at a CAGR of 7.90% from 2023 to 2032. The market is expected to reach USD 36.41 billion by 2032. Antidepressants are professionally prescribed drugs that assist with treating depression.
Xanamem = No Side Effects + Lower levels of depression + 3.6 EOT within FDA guidelines for a prescribed anti depressant (see above)
An excellent presentation by the Actinogene CEO on market online.com.au with Sonia Madigan
DYOR
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.001(4.76%) |
Mkt cap ! $69.89M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $25.26K | 1.175M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2003434 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1324445 | 9 |
View Market Depth
| Last trade - 14.28pm 25/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |